Dr. Siefker-Radtke on Next Steps With Erdafitinib in Bladder Cancer

Video

In Partnership With:

Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses next steps with erdafitinib in patients with bladder cancer.

Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses next steps with erdafitinib in patients with bladder cancer.

In March 2018, the FDA granted a breakthrough therapy designation to the oral pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib for the treatment of patients with metastatic bladder cancer. This designation was based on findings from a phase II study, which showed that more than 40% of patients with metastatic or unresectable bladder cancer responded to treatment with erdafitinib. Of the 99 patients on the trial, 40 responded to treatment, and an additional 39 patients had stable disease.

As a result of these findings, there are plans for a large phase III trial. This trial will explore the question of whether patients with FGFR-altered tumors respond differently to an FGFR-targeted therapy compared to immunotherapy. Patients who have not had prior immunotherapy will be randomized to either immunotherapy or erdafitinib. Patients who have had prior immunotherapy will be randomized to either erdafitinib, or a single-agent taxane or vinflunine, depending on location.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,